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Summary 
T  lymphocytes have been implicated in  controlling the  recruitment of eosinophils into  the 
lung in murine models of allergic asthma. The mechanism by which T  cells assist in the recruit- 
ment of eosinophils to the lung in these models is not completely understood. We hypothe- 
sized that eosinophil-active chemokines might be regulated by antigen (Ag)-induced T  cell ac- 
tivation in vivo and  thereby mediate  T  cell-dependent eosinophil recruitment. To test this 
hypothesis, we examined the effect of an anti-CD3  mAb on Ag-induced pulmonary eosino- 
philia and correlated this with the expression of three eosinophil-active chemokines: eotaxin, 
macrophage inflammatory protein (MIP)-lot, and RANTES. We found that Ag-induced pul- 
monary  eosinophilia  was  associated  with  the  induction  of eotaxin  and  MIP-lc~,  but  not 
RANTES  mlKNA.  PrechaUenge treatment with  anti-CD3  mAb  inhibited  eotaxin, but  not 
MIP-lot and RANTES mlKNA induction, and significantly reduced eosinophil accumulation 
in the lung.  In addition, Ag-specific antibody responses and mast cell degranulation after Ag 
challenge in sensitized mice were not affected by T  cell elimination, and were not sufficient to 
induce the expression of eotaxin and cause pulmonary eosinophilia. These findings suggest that 
eotaxin is one of the molecular links between Ag-specific T  cell activation and the recruitment 
of eosinophils into the airways. 
"1• 
ronchial  inflammation  is  a  characteristic  pathologic 
~feature  of allergic  asthma  (1,  2).  Activated  CD4  +  T 
lymphocytes, eosinophils, and mast cells are present in the 
cellular infiltrate in  asthma  and  each  of these  cells  is be- 
lieved to contribute to the pathogenesis of this disease (3-5). 
CD4 + T  lymphocytes play an important role in regulating 
the immune response to Ag, in part through the secretion 
of cytokines. CD4 + lymphocytes can be segregated on the 
basis of cytokine secretion patterns into Thl and Th2 cells 
(6). Th2 cells are important mediators ofaUergic inflamma- 
tory responses as they secrete cytokines that  promote the 
maturation  and  activation of eosinophils  (IL-3,  IL-5,  and 
GM-CSF)  (7), the growth and differentiation of mast cells 
(IL-3,  GM-CSF,  and  IL-10)  (8),  and regulate the Ig class 
switch to favor the development of Ag-specific IgE Ab re- 
sponses (IL-4) (9). 
Murine  models  of Ag-induced pulmonary eosinophilia 
and airway hyperreactivity have been developed to facili- 
tate the study of cellular immune responses in asthma  (10- 
15).  Pulmonary eosinophilia and  airway hyperresponsive- 
hess  can be  attenuated  in  these  models  by eliminating T 
cells with either anti-CD4 (12,  16) or anti-Thyl (15) mAb, 
by the  administration  of neutralizing Abs  to  IL-4  (14)  or 
IL-5 (10,  16), and in IL-5-deficient mice (17), demonstrat- 
ing  the  importance  of Th2  cells  and  cytokines in  these 
models. 
The importance of tissue  eosinophilia in allergic airway 
disease  is  inferred from studies  linking  eosinophil-derived 
granular proteins and lipid metabolites to airway hyperre- 
sponsiveness  (4,  18),  and  from clinical studies  correlating 
the remission of asthma  symptoms with the  resolution of 
airway eosinophilia  (19-21).  These observations implicat- 
ing eosinophils in the pathogenesis of asthma make it likely 
that  understanding the  mechanisms  of eosinophil recruit- 
ment to the airways will offer new therapeutic approaches 
for the treatment of this important human disease. 
There is  an  emerging but  incomplete body of knowl- 
edge defining the mechanisms that lead to the recruitment 
and retention of airway eosinophils.  Leukocyte extravasa- 
tion is exquisitely regulated in vivo by a series  of coordi- 
nated leukocyte-endothelial cell interactions involving sev- 
eral families  of molecular regulators, such as the selectins, 
the  integrins,  and  the  chemokines  (22,  23).  The  chemo- 
kines are a large family of inducible cytokines that are potent 
chemoattractants ofleukocytes (24). They are classified into 
three families (or, 13, and ~/) based on the sequence of con- 
served cysteine residues in their primary structure. Eotaxin 
is a recently described 13-chemokine that has been shown 
to  specifically chemoattract eosinophils in  the guinea pig, 
mouse, and human (25-29). Other chemokines with chemo- 
tactic activity for eosinophils include monocyte chemoat- 
tractant proteins 2  and  3,  macrophage inflammatory pro- 
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Volume 184  October 1996 1461-1469 tein-lot (MIP-lcx)  1, RANTES, and IL-8 (30). However, of 
these  chemokines,  only eotaxin  has  specific  chemoattrac- 
tant activity for eosinophils. 
While  chemokines  often  have  overlapping activities in 
vitro, it is their disease-specific expression and  the  timing 
and location of their production that dictate their role in a 
given inflammatory disease. This pattern of expression will 
be determined by the mechanisms of chemokine regulation 
in vivo. In an effort to understand the chemokines relevant 
to  allergic pulmonary inflammation, we  examined the ex- 
pression and regulation of three  eosinophil-active chemo- 
kines: MIP-lc~, RANTES, and eotaxin, in a murine model 
of antigen-induced pulmonary  eosinophilia.  Our  findings 
demonstrate that eotaxin is regulated in vivo by Ag--specific 
T  cells, and not by mast cells and IgE, and support the hy- 
pothesis that  eotaxin is  an  important  regulator of pulmo- 
nary eosinophilia. 
Materials  and Methods 
Mice.  BALB/cJ  (H-2  a)  mice  between  5  and  10  wk  of age 
were obtained from The Jackson Laboratory (Bar Harbor, ME). 
The  mice  were  housed  in  a  pathogen-free  animal  facility and 
were given food and water ad lib. 
Immunization  and Challenge Protocol.  Mice were immunized with 
10 Dg of OVA (Sigma Chemical Co., St. Louis, MO) and 1 mg 
aluminum  hydroxide  intraperitoneally on  days  0,  7,  and  14. 
Sham-immunized  mice  received  aluminum  hydroxide  alone. 
Mice underwent aerosol challenge with OVA (50 mg/ml in ster- 
ile saline)  7-10 d after the final immunization. Ag challenge was 
performed by placing mice in a Plexiglas box (dimensions: 22  ￿ 
23  ￿  14 cm) and aerosolizing OVA using a nebulizer (DeVilbiss 
Co., Health Care Division, Somerset, PA), driven by compressed 
air, for 20 min. Mice were killed at 3, 6, 24, and, in some experi- 
ments, 48 h after challenge. A minimum of three mice were in- 
cluded in each group at each time point. 
Ab Administration.  The rat anti-mouse CD3~ mAb was gen- 
erously  provided  by  K.  Bottomly  (Yale  University  School  of 
Medicine, New Haven, CT)  (clone YCD3,  isotype IgG2b) (31). 
The Ab was raised as ascites, subjected to a 50% ammonium sul- 
fate precipitation, dialyzed extensively against normal saline,  and 
sterile filtered (0.2  bLm filter)  before use. An isotype-matched Ab 
(rat IgG26; ICN Biomedicals, Inc., Costa Mesa, CA) was used as a 
control Ab.  Mice were  injected intravenously with  either anti- 
CD3 mAb or control Ab (r  btg/dose) i.v. on each of the two 
days preceding secondary challenge with OVA by aerosol. 
Bronchoalveolar lavage (BAL).  BAL was performed at 3,  6, 24, 
and  48  h  after aerosol challenge.  Mice were  anesthetized with 
chloral hydrate (400  btg/g). The lungs and heart were surgically 
exposed. The lungs were perfused with normal saline to remove 
blood. The trachea was  canulated with polyethylene tubing and 
the lungs were lavaged with eight 0.5-ml aliquots of PBS  con- 
taining 0.6 mM EDTA. Recovered live cells (trypan blue exclu- 
sion)  were  enumerated  in  a  hemocytometer.  Cell  differential 
counts  were  determined by enumerating macrophages, neutro- 
phils, eosinophils, and lymphocytes on Wright-stained (LEUKO- 
STAT;  Fisher  Scientific  Co.,  Pittsburgh,  PA)  cytocentrifuge 
preparations of cells recovered by BAL. 
~Abbreviations used in this paper: BAL, bronchoalveolar lavage; MIP, mac- 
rophage inflammatory protein; rp, ribosomal protein. 
Histology.  Lungs were harvested at 3,  6,  24,  and  48  h  after 
aerosol challenge, fixed in 10% formalin, and embedded in paraf- 
fin blocks. Lung sections (5 I~m) were stained with hematoxylin 
and eosin using standard protocols. Peribronchial and perivascular 
eosinophils were  counted in  a  minimum  of five high-powered 
fields (magnification, X40)  and expressed as the number of eosi- 
nophils per length of basement membrane. 
RNA Extraction and Northern Blotting.  Lungs  excised for RNA 
extraction were perfused with sterile saline  to remove blood and 
then frozen in liquid nitrogen and stored at  -70~  before pro- 
cessing.  Total cellular RNA was  isolated from the lungs by ho- 
mogenizing the tissue  with a Polytron (Brinkmann Instruments, 
Inc., Westbury, NY) in 4 M guanidine hydrochloride and pellet- 
ing the RNA through a 5.7-M CsC12 cushion (32).  10 p,g of total 
RNA  was  fractionated on  a  1.2%  agarose gel containing 0.7% 
formaldehyde  and  then  transferred  to  GeneScreen  (DuPont, 
Wilmington, DE) and hybridized with 32p[dCTP]  Klenow-labeled 
random-primed mous.e eotaxin, mouse MIP-loq mouse RANTES, 
and mouse ribosomal protein (rp)L32  cDNA probes. The eotaxin 
probe was a full-length mouse eotaxin cDNA (26) and the MIP- 
lc~  and  R_ANTES  probes  were  ~300-bp  coding  fragments, 
kindly provided by Drs. Richard Young (Massachusetts  Institute 
of Technology, Cambridge,/VIA) and Glenn Dranoff (Dana Farber 
Cancer Institute, Boston, MA), respectively. The ribosomal pro- 
tein (rb) L32 probe is a 279-bp fragment encoding the ribosomal 
protein rpL32  and was  used to  control for RNA  loading (33). 
Hybridization was  performed in  50%  formamide,  10%  dextran 
sulfate,  5￿  SSC,  1￿  Denhardt's  solution  (0.0002%  [wt/vol] 
polyvinylpyrrolidone, 0.0002%  [wt/vol] BSA, 0.0002%  [wt/vol] 
Ficoll 400),  and  100  btg/ml  of heat-denatured  herring  sperm 
DNA  solution,  1%  (wt/vol)  SDS,  and  20  mM  Tris pH  7.5  at 
42~  for 18 h. Blots were washed with 2￿  SSC/0.1% SDS at 42~ 
for 40 min and then in 0.2￿  SSC/0.1% SDS at 65~  for 40 min. 
Lung Digests.  Lung digests were performed as previously de- 
scribed (34).  Briefly, lungs were perfused with  sterile saline via 
the pulmonary artery to remove blood. Excised lung tissue  was 
minced with  scissors,  resuspended in  digest medium containing 
RPMI 1640,  10% FCS, DNAse (50 U/ml; Sigma Chemical Co.), 
and  collagenase  (150  U/ml;  Worthington  Biochemical  Corp., 
Freehold, NJ), and placed in a shaker bath at 200 rpm for 90 min 
at 37~  After digestion, the tissue was dispersed through an 80-~m 
mesh steel screen and passed through sterile gauze to remove de- 
bris  and  to  produce  a  single  cell  suspension.  The  cells  were 
washed three times in RPMI 1640 and counted in a hemocytom- 
eter. The cells were further purified by density gradient centrifu- 
gation using Lympholyte-M (Accurate Chemical  and  Scientific 
Corp., Westbury, NY). 
Flow Cytometry.  Three-color flow cytometry was  performed 
as previously described (35).  Commercial conjugated Abs  used 
for cell staining included: anti-murine  CD4-PE  (clone  GKI.5) 
(Becton Dickinson and Co.,  San Jose,  CA), anti-murine CD8- 
red 613  (clone 53-6.7)  (GIBCO BRL,  Grand Island,  NY),  goat 
anti-rat IgG-FITC (mouse serum adsorbed) (Kirkegaard & Perry 
Labs,  Inc.,  Gaithersburg,  MD).  Protein  G-purified  anti-CD3 
mAb (clone YCD3)  was  conjugated using the Quick Tag FITC 
conjugation kit (Boehringer Mannheim Corp., Indianapolis, IN), 
as per instructions provided by the manufacturer. Cell suspensions 
from lung digests were resuspended in staining buffer (PBS with 
10%  mouse  serum) before fluorescence staining. Samples of 106 
cells were stained with the conjugated Abs at 4~  for 30 rain. Af- 
ter washing with PBS, the cells were fixed with 1% paraformalde- 
hyde. Single and three-color flow cytometry was performed on a 
FACScan  |  (Becton  Dickinson  and  Co.)  cytofluorimeter  and 
1462  T Cell-dependent Eotaxin Induction In Vivo Figure 1.  Kinetics of pulmonary  chemokine mRNA expression and eosinophil accumulation  in lung and BAL after Ag challenge. (A) Northern blot 
analysis of 10 txg of total lung t(NA extracted from nonimmunized, nonchallenged  mice (Normal) (lanes 1 and 2); sham-immunized  mice (lanes 3, 4, 8, 
9, 13, and  I4); or OVA-immunized mice (lanes 5-7,  10--12, 15-20) after challenge with aerosolized OVA. Tissue was harvested at 3, 6, 24, or 48 h. The 
blot was sequentially hybridized  with eotaxin, MIP-la, RANTES, and rpL32 32p-labeled cDNA probes and exposed for 1 d (except lanes I a and 2 a, 
which were exposed for 4 d to demonstrate  baseline lung eotaxin expression in normal mice), 1 d, 10 d, and 4 d, respectively. Each lane represents an in- 
dividual mouse from a representative experiment  (n =  3). (B) Quantification  ofperibronchial and perivascular eosinophils from sham- and OVA-immu- 
nized mice at sequential time points after aerosol OVA challenge. Data represent  the mean  -+ SEM of eosinophils per millimeter basement membrane 
from five fields (￿  40) from a representative  experiment.  (C) Quantification  ofeosinophils recovered from BAL from sham- and OVA-immunized mice 
at sequential time points after aerosol challenge. Data represent mean 4- SEM ofeosinophils;  minimum of three mice per group. 
analysis  was  performed  using  Lysys  software  (Hewlett-Packard 
Co., Palo Alto, CA). 
OVA-specific IgG and IgE Leve/s.  OVA-specific IgG levels were 
measured  by  EL1SA  using  96-well  microtiter  plates  (Costar 
Corp.,  Cambridge,  MA).  The plates  were  coated with  OVA in 
PBS  overnight at  4~  and  then  washed  three  times  with  PBS- 
Tween  (0.5  ml  Tween-20  [Sigma  Chemical  Co.]  in  1L  PBS). 
The plates were blocked with PBS-10% FCS (Hazelton Biologi- 
cals  Inc.,  Lenexa,  KS)  at  room temperature  for 2  h  and  washed 
three  times  in  PBS-Tween.  Serum  samples  were  added  to  the 
wells after serial dilution in PBS-10%  FCS and were allowed to 
incubate  for  1 h  at  room temperature.  The  plates  were  washed 
five times with PBS-Tween before the addition of the secondary 
Ab, a goat anti-mouse  IgG alkaline phosphatase  (Vector Labora- 
tories,  Burlingame,  CA)  for  45  min  at  room  temperature.  The 
plates were washed 5  times with PBS-Tween and  10 times with 
distilled  water  before  development  with  phosphatase  substrate 
(Kirkegaard  &  Perry  Laboratories,  Inc.).  The  reaction  was  al- 
lowed to proceed for 20 min and was stopped by the addition of 
dilute sulfuric acid. The plates were read in an ELISA plate reader 
at OD 405 nm. 
OVA-specific  IgE  levels  were  measured  by  capture-ELISA. 
ELISA microtiter plates  (Nunc  Inc., Naperville, IL) were coated 
with  a  purified  anti-mouse  IgE mAb  (Pharmingen,  San  Diego, 
CA) at a concentration of 2  p~g/ml in 0.1 M  NaHCO 3 overnight 
at  4~  The  plates  were  washed  with  PBS-Tween  and  blocked 
with  PBS-10%  FCS.  Serum  samples  were  diluted  in  PBS-10% 
FCS and incubated in the wells for 2 h. After washing with PBS- 
Tween, biotinylated-OVA (10 p~g/ml) was added to the wells for 
1 h.  The plates  were washed  with PBS-Tween followed by the 
addition ofavidin alkaline phosphatase  (Vector Laboratories)  for 1 h. 
The plates were washed with PBS-Tween and distilled water, be- 
fore the addition of the phosphatase substrate.  The plates were al- 
lowed to develop overnight in the dark.  The plates were read in 
an ELISA plate reader at OD 405 nm. 
BAL Histamine Determination.  BAL was performed on groups 
of four mice, 30 rain after aerosol challenge with either saline or 
OVA  (50  mg/ml).  BAL was  performed  with  two  1-ml  washes 
with  ice-cold saline.  The  collected fluid was  centrifuged  to  re- 
move cells and histamine was measured by enzyme immunoassay 
(Immunotech,  Marseille, France) as per the instructions provided 
by the manufacturer. 
Results 
Induction  of Eotaxin and MIP- l c~ but not RANTES  mRNA 
after Airway Ag Challenge in Sensitized Mice.  The  kinetics 
1463  MacLean et al. Figure 2.  Effect of anti-CD3 mAb on pulmonary chemokine mRNA and eosinophil accumulation  in OVA-immunized mice after challenge. (A) 
Northern blot analysis  of 10 Ixg of total lung RNA from OVAqmmunized mice pretreated with the control Ab (IgG2b) (lanes  3, 4, 7, 8,  11-14)  or anti- 
CD3 mAb (ecCD3) (lanes  5, 6, 9,  10,  15-18)  and then challenged  with aerosohzed OVA. Lung tissue was harvested 3, 6, and 24 h after challenge. Also in- 
cluded are lungs from nonimmunized, nonchallenged control mice (lanes 1 and 2).  The blot was sequentially  hybridized with eotaxin, MIP-I~x, 
RANTES, and rpL32 32p-labeled  cDNA probes and exposed for 4, 10, 3, and 4 d, respectively. Each lane represents an individual  mouse from a repre- 
sentative experiment  (n = 3). (B) Quantification  ofperibronchial  and perivascular  eosinophils  from OVA-immunized  mice treated with either the isotype 
control Ab or anti-CD3 mAb, at sequential  time points after aerosol challenge. Data represent the mean 2  SEM ofeosinophils per lnillimeter  basement 
membrane from five fields (￿  40) from a representative experiment. (C) Quantification  of eosinophils  recovered from BAL of OVA-immunized  mice 
treated with either the isotype control Ab or anti-C1)3 mAb, at sequential  time points after aerosol challenge, Data represent mean +- SEM of eosino- 
phils; minimum of three mice per group. 
of eosinophil chemokine mRNA expression was examined 
in  sham-  and  OVA-immunized mice  at  sequential time 
points  after  aerosol  challenge  with  OVA.  Low  levels  of 
constitutive expression of eotaxin mRNA were detected in 
the lungs ofnonimmunized, nonchallenged mice (Fig. 1 A, 
lanes  la  and 2a).  An increase in eotaxin mRNA  was  de- 
tected  in the  OVA-immunized mice  3  h  after  challenge, 
reached  a  peak  at  6  h  after  challenge, and remained ele- 
vated at 24 and 48 h  (Fig.  1 A). Eotaxin mRNA remained 
at prechallenge levels in the sham-immunized mice. MIP- 
lot  mRNA  was  also  increased 3  h  after  challenge in the 
OVA-imnmnized mice, peaked at 6 h, but returned to un- 
detectable levels by 24 h  (Fig. 1 A). MIP-lo~ mRNA levels 
did not change in the sham-immunized mice. Constitutive 
expression of RANTES mRNA  was  detected in nonim- 
munized mice and did not change significantly in either the 
sham- or  OVA-imnmnized mice after  challenge over the 
time period studied when compared with levels of mRNA 
for the rpL32, used as a control for RNA loading (Fig. 1 A). 
Ag-induced  Pulmonary  Eosinophilia  Correlates  with  b~duction 
of Eotaxin  and MIP- l ol mRNA.  The  kinetics  of  eosino- 
phil accumulation into lung tissue and into the airway lu- 
men of sham- and OVA-immunized mice was  examined 
in  parallel  to  the  expression  of  eotaxin,  MIP-ler  and 
RANTES  mRNA.  No  eosinophils were  present  in  the 
lung (Fig.  1  B)  or recovered from BAL (Fig.  1  C)  before 
challenge (time 0  h) in either group. 3  h  after challenge, a 
perivascular accumulation of inflammatory ceils  could be 
seen in the lungs of OVA-immunized mice that consisted 
of  neutrophils,  mononuclear  cells,  and  rare  eosinophils 
(Fig.  1 B)  and a small number of eosinophils were recov- 
ered  from  BAL  (Fig.  I  C).  By  6  h  after  challenge,  the 
perivascular accumulation of eosinophils had progressed in 
the OVA-immunized  mice, and eosinophils were now also 
identified peribronchially (Fig.  1  /3). Eosinophils  consti- 
tuted ~5% of the cells recovered from the BAL of OVA- 
1464  .  T Cell-dependent Eotaxin Induction In Vivo Figure 3.  Reduction in peribronchial and perivascular inflammation after treatment with anti-CD3 mAb. Histologic analysis of lungs from OVA- 
immunized mice treated with either the isotype control Ab (A, C) or anti-CD3 mAb (B, D), 24 h after aerosol challenge. Note the peribronchial (A) and 
perivascular (C) inflammation  with eosinophils (arrows)  in the mice treated with control Ab compared with the lung from the anti-CD3-treated mice (B, 
peribronchial; D, perivascular). Lung tissue was stained with hematoxylin and eosin. (￿  350). Sections shown are from a representative experiment. 
immunized  mice  at  6  h  (Fig.  1  C).  At  24  and  48  h,  a 
marked  perivascular  and  peribronchial  accumulation  of 
eosinophils was present in the OVA-immunized mice (Fig. 
1 B) and >35% of cells recovered from BAL were eosino- 
phils  (Fig.  1  C).  In contrast,  lungs  from sham-immunized 
mice  showed  no  perivascular  or  peribronchial  inflamma- 
tion over the time period studied  (Fig.  1 B) and no eosino- 
phils were recovered from BAL (Fig. 1 C). 
Anti-CD3 Inhibits Eotaxin but not MIP- lol and RANTES 
mRNA  Expression while  Eliminating  Ag-induced  Pulmonary 
eosinophilia.  It is known that T  cell elimination can inhibit 
Ag-induced pulmonary eosinophilia in the mouse  (10,  12, 
15,  16).  We  hypothesized  that  T  cell  elimination  may  di- 
minish  pulmonary  eosinophilia  by  modulating  eosinophil 
chemokine mlkNA expression.  To test  this  hypothesis, a  rat 
anti-mouse CD3 mAb was administered to OVA-immunized 
mice on two consecutive days before challenge; OVA-immu- 
nized control mice received an isotype-matched Ab (IgG2b). 
Anti-CD3 mAb effectively reduced both CD4 + and CD8 + 
lymphocytes from the lung compared with mice receiving 
the  control Ab,  as  assessed  by flow  cytometric  analysis  of 
cells  recovered from enzymatic lung digests,  resulting in  a 
>95%  reduction  in  total  T  lymphocytes  recovered  from 
lung digests, compared with controls (data not shown). 
OVA-immunized  mice  treated  with  anti-CD3  mAb 
showed diminished  eotaxin mRNA  induction at 3, 6, and 
24  h  after  challenge  compared  with  immunized  mice 
treated with an isotype-matched control Ab (Fig. 2  A).  In 
marked contrast, anti-CD3 actually prolonged MIP-1 0~ in- 
duction until  24 h  and induced RANTES mRNA  at 3,  6, 
and 24 h  (Fig. 2 A). The diminished  expression of eotaxin 
mR.NA in the anti-CD3-treated mice was accompanied by 
a significant reduction in tissue  eosinophilia  (Fig.  2  B, and 
Fig. 3, B and D)  and the number of eosinophils recovered 
by BAL (Fig. 2  C). OVA-immunized mice treated with the 
control  Ab  showed  an  increase  in  eotaxin  and  MIP-lo~ 
mR.NA (Fig. 2 A) that was similar to that seen in untreated 
immunized mice after challenge  (Fig.  1 A), demonstrating 
that  the  control Ab did  not significantly affect the  induc- 
tion  of chemokine  mRNA.  Likewise,  treatment  with  the 
control Ab did not affect the development ofperibronchial 
and  perivascular  inflammation  with  eosinophils  (Fig.  2  B, 
and  Fig.  3, A  and  C)  or the recruitment  of eosinophils to 
the airway lumen (Fig. 2  C). 
Anti-CD3 Induces MIP-loe and RANTES mRNA but not 
Eotaxin  or  Pulmonary Eosinophilia in  Sham-immunized  Mice. 
The  divergent  expression  of eotaxin  versus  MIP-10~  and 
P,  ANTES  mRNA  expression  in  response  to  anti-CD3 
1465  MacLean et al. Figure 4.  Induction of MIP-lct and R.ANTES but not eotaxin  mRNA 
in sham-immunized  mice. Northern analysis  of 10 p.g of total lung P,  NA 
isolated at 3, 6, and 24 h from sham-immunized  mice after control Ab 
treatment (lgG2b) (lanes 1, 2,  5,  6,  9-11)  or anti-CD3 rnAh treatment 
(lanes 3, 4,  7, 8,  I2-14).  The blot was sequentially  hybridized  with eo- 
taxin, MIP-lot, R_ANTES, and rpL32 32p-labeled  cDNA probes and ex- 
posed for 3 days, 3 d, 10 d, and 4 d, respectively.  Each lane  represents an 
individual  mouse from a representative  experiment (n = 2). 
treatment  in  OVA-immunized mice  was  an  unexpected 
finding. This was further investigated by comparing the ef- 
fects of Ab treatment in sham-immunized mice. Anti-CD3 
induced  both  MIP-lot  and  R_ANTES  but  not  eotaxin 
mRNA  in sham-immunized mice,  while  the  control Ab 
had no effect on chemokine mR.NA expression (Fig. 4). It 
is notable that the induction of MIP-lot and R.ANTES was 
not accompanied by significant tissue eosinophilia (0 eosin- 
ophils/mm in both perivascular and peribronchial areas  for 
all time points studied) and no eosinophils were recovered 
from BAL. 
OVA-specific IgG and IgE  Titers  and BAL Histamine Levels 
Are  Unchanged  by  Treatment  with  anti-CD3  mAb  in  OVA- 
immunized Mice.  Anti-CD3  effectively  eliminated  Ag- 
induced pulmonary eosinophilia and eotaxin induction in 
OVA-immunized mice, suggesting that eosinophil recruit- 
ment and eotaxin are T  cell dependent in this model.  To 
determine whether Ag-specific Ab responses and mast cell 
degranulation can  be  dissociated from  eotaxin  expression 
and  eosinophil  recruitment,  we  examined  the  effect  of 
anti-CD3 treatment on  OVA-specific IgG  and IgE  titers 
and BAL  histamine levels  in  OVA-immunized mice.  As 
expected,  control animals developed significantly elevated 
titers  of both  OVA-specific IgG and IgE  compared  with 
sham-immunized controls (Fig. 5, A  and B).  Treatment of 
OVA-immunized mice with  the  anti-CD3 mAb did  not 
significantly alter  the  titers  of OVA-specific  IgG  or  IgE 
compared with mice receiving the isotype control Ab (Fig. 
5, A  and B). 
Mast cell degranulation was assessed  by measuring BAL 
histamine levels in sham- and OVA-immunized mice after 
airway challenge with either saline or OVA. Sham-immu- 
nized nfice, challenged with  OVA,  showed no significant 
elevation of BAL  histamine level  compared  with  saline- 
Figure 5.  OVA-specific  IgG and IgE titers are unchanged  by treatment 
with anti-CD3 n~b. OVA-specific  IgG and IgE were measured from se- 
rum obtained 24 h after aerosol challenge. (A) OVAqmmunized mice 
treated with the isotype control mAb on the 2 d before challenge (closed 
circles) had  elevated titers of OVA-specific IgG that were significantly 
greater than nonimmunized controls (open circles) (*P <0.01). Treatment 
of OVA-immunized  mice with anti-CD3 mAb on the 2 d before second- 
ary challenge  did not significantly  alter titers of OVA-specific IgG (hatched 
circles) compared with OVA-immunized mice treated with the control 
Ab. (B) OVA-immunized mice treated with the isotype control Ab had 
elevated titers of OVA-specific IgE compared with nonimmunized con- 
trols (tP <  0.01). Treatment of OVA-immunized mice with anti-CD3 
mAb on the 2 d before secondary  challenge  did not significantly  alter ti- 
ters with OVA-specific IgE compared to OVA-immunized  mice treated 
with the control Ab (~ P = 0.46). Data represent mean OD -+ SEM of 
serum samples from at least three separate experiments (minimum three 
mice/group). OVA-specific IgG was assayed at fivefold serial dilutions 
from 1:2(1 to 1:62,500. OVA-specific  lgE was assayed at a dilution of 1:3. 
challenged  mice  (Fig.  6).  In  contrast,  OVA-immunized 
mice,  challenged with  OVA,  had  an elevated BAL hista- 
mine level compared with saline-challenged mice and this 
was not affected by treatment with either the isotype con- 
trol Ab or with the anti-CD3 rnAb (Fig. 6).  This demon- 
strates that Ag-induced mast cell degranulation can be dis- 
sociated from pulmonary eosinophilia and eotaxin induction 
in this model. 
1466  T Cell-dependent  Eotaxin Induction In Vivo Figure 6.  BAL histamine levels in sham- and OVA-immunized mice 
after challenge. BAL histamine levels were measured in sham- and OVA- 
immunized mice after  aerosol challenge with either saline or OVA. Hista- 
mine levels in sham-immunized  mice were similar after challenge with 
either saline or OVA. In contrast, OVA-immunized  mice treated with ei- 
ther isotype-control  Ab or anti-CD3 mAb showed a significant increase 
in  BAL  histamine after challenge with OVA  compared with OVA- 
immunized mice challenged with saline (*P <0.048 and J" P <0.01, re- 
spectively). Data represent the mean ~  SEM BAL histamine; minimum 
of three mice per group. 
Discussion 
In this study, we examined the expression and regulation 
of  eosinophil-active  chemokines  in  vivo,  in  a  murine 
model of allergic pulmonary inflammation. We found that 
eotaxin and MIP-let mRNA were rapidly induced after Ag 
challenge in immunized mice with levels detectable by 3 h 
and  peaking  by  6  h.  This  initial  increase  in  eotaxin  and 
MIP-10t levels preceded the recruitment of eosinophils into 
the  lung  and  airway lumen  (BAL),  suggesting  that  these 
chemokines may play an  important role  in  recruiting  eo- 
sinophils to the lung. However, by 24 to 48 h when eosin- 
ophil  infiltration  was  peaking,  eotaxin  levels  were  still 
markedly elevated, while MIP-le~ levels returned to base- 
line.  In  contrast,  R_ANTES  mRNA  expression  was  un- 
changed  after  challenge,  suggesting  that  the  induction  of 
this chemokine is not critical for the recruitment of eosino- 
phils in this model. 
T  lymphocytes have been implicated in  controlling the 
recruitment of eosinophils into the lung in murine models 
of allergic  asthma.  Ag-specific  CD4 +  Th2  lymphocytes 
play a central role in eosinophil recruitment, as depletion of 
these cells (12,  15) or their secreted products (IL-4 and IL-5) 
(10,  14,  16,  17),  significantly reduces pulmonary  eosino- 
philia.  The  mechanism by which  T  cells  assist  in  the  re- 
cruitment of eosinophils to the lung in these models is not 
completely understood.  We  hypothesized  that  eosinophil 
active chemokines may be regulated by Ag-induced T  cell 
activation in  vivo and  thereby mediate  T  cell-dependent 
eosinophil recruitment.  To test this hypothesis, we exam- 
ined the  effect of an anti-CD3  mAb on Ag-induced pul- 
monary eosinophilia and correlated this with the expression 
of eotaxin, MIP-lot, and KANTES mRNA. Anti-CD3 ef- 
fectively  inhibited  eotaxin  mRNA  expression  in  immu- 
nized  mice  a~er airway challenge  and  this  was  associated 
with a significant reduction in pulmonary eosinophilia.  In 
contrast,  anti-CD3  actually  induced  both  MIP-let  and 
RANTES  mRNA  expression;  this  was  observed in  both 
sham- and OVA-immunized mice. Importantly, the induc- 
tion of MIP-1ot and RANTES mRNA was not associated 
with  pulmonary eosinophilia.  These findings  demonstrate 
that the induction  of eotaxin in vivo is dependent on Ag- 
specific  T  cells,  and  that  its  expression  can  be  dissociated 
from MIP-lc~ and RANTES in anti-CD3 treated mice. 
The correlation of diminished eotaxin, but not MIP-let 
or R_ANTES mRNA expression, with reduced pulmonary 
eosinophilia  in  anti-CD3-treated  mice,  suggests  that  eo- 
taxin may be a key regulator of pulmonary eosinophilia and 
the  critical eosinophil  chemoattractant in  this  model.  Eo- 
taxin was originally isolated as the predominant eosinophil 
chemoattractant in the lung lavage fluid of sensitized guinea 
pigs  after allergic  exposure  (25).  In  contrast  to  other  eo- 
sinophil-active chemoattractants,  eotaxin is unique  in that 
it  specifically  attracts  eosinophils.  This  specificity has  re- 
cently been demonstrated in vitro for both mouse and hu- 
man eotaxin in chemotaxis and calcium flux assays (26-29, 
36).  The  in  vivo potency and  specificity of eotaxin have 
been  confirmed in studies  demonstrating tissue  eosinophil 
recruitment after instillation into the airways of rodents and 
after injection into the skin of rodents and rhesus monkeys 
(28,  29,  37).  Furthermore,  eotaxin acts synergistically with 
IL-5, another eosinophil-specific cytokine, to produce tis- 
sue eosinophilia in the skin of guinea pigs (38) and the skin 
and lungs of mice (36).  The specificity and potency of eo- 
taxin for eosinophils are the result of its high affinity inter- 
action with recently described [3-chemokine receptor, CKR3, 
that  is  highly  expressed  in  human  and  mouse  eosinophils 
(39,  40). 
The major cellular sources of eotaxin are thought to be 
the  epithelium,  the endothelium,  and activated infiltrating 
leukocytes, like  eosinophils  (27-29).  We  have found that 
TNF-et,  IL-1,  and  IFN-~/ regulate  the  expression  of eo- 
taxin in  epithelial  and  endothelial  cells  in  vitro  (27).  The 
inhibition  of Ag-induced  eotaxin  mRNA  expression  by 
anti-CD3  may result from the elimination of T  cell--derived 
factors that induce  eotaxin mRNA expression in  eotaxin- 
producing cells in the lung. Alternatively, ifT lymphocytes 
are an important source of eotaxin in vivo, anti-CD3 may 
exert its effect directly, by eliminating these cells.  Finally, T 
cell activation and cytokine release after the administration 
of anti-CD3  (41,  42),  may result in  the  production  of an 
inhibitory cytokine that is not produced by T  cells after ac- 
tivation by Ag. In contrast to eotaxin, MIP-la and RANTES 
were  induced  by  anti-CD3  treatment,  demonstrating  that 
these  chemokines are regulated by a fundamentally different 
mechanism than eotaxin in vivo. 
Ag-specific Abs are thought to  contribute  to inflamma- 
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reactions)  via  IgE-mediated  degranulation  of  mast  cells 
(43). Administration of anti-CD3 after primary immuniza- 
tion allowed us to assess the role of T  cell depletion on eo- 
taxin induction and pulmonary eosinophilia in the presence 
of Ag-specific Abs and activated mast cells. We found that 
treatment with anti-CD3 did not significantly alter titers of 
Ag-specific IgG  and  IgE  or the  release of histamine  from 
mast cell after Ag challenge in immunized mice. Yet, anti- 
CD3  significantly reduced eotaxin expression and pulnm- 
nary eosinophilia, suggesting that in the absence of T  cells, 
Ag-specific IgE  and  IgG Abs  and  mast  cell degranulation 
were not sufficient to induce eotaxin expression or to pro- 
duce pulmonary eosinophilia after Ag challenge. 
In  summary,  we  have  demonstrated  that  Ag-induced 
pulmonary eosinophilia was  associated with  the induction 
of eotaxin and  MIP-lci but  not  RANTES  mRNA.  Pre- 
challenge treatment with anti-CD3 mAb inhibited eotaxin 
but not MIP-1ot and RANTES  mRNA  induction and sig- 
nificantly reduced eosinophil accumulation in the lung.  In 
addition, Ag-specific Ab responses and mast cell degranula- 
tion after Ag challenge in sensitized mice were not affected 
by T  cell elimination and were not sufficient to induce the 
expression  of eotaxin  and  cause  pulmonary  eosinophilia. 
These findings suggest that eotaxin may be one of the mo- 
lecular links between Ag-specific T  cell activation and the 
recruitment of eosinophils into the airways. 
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